The complaint targets alleged violations of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a). According to the legal filing, Capricor modified its statistical analysis framework for Deramiocel but proceeded with a Biologics License Application resubmission despite failing to reach an agreement with regulators regarding these changes. The DJS Law Group is currently representing investors affected by the subsequent market volatility.

Shareholders who purchased CAPR stock during the designated class period face a September 28, 2026, deadline to seek appointment as lead plaintiff. David J. Schwartz of DJS Law Group notes that participation in the recovery process does not strictly require this lead designation. The firm, which specializes in securities litigation and corporate governance, is urging those who suffered financial losses to come forward to review their legal standing in the case.